Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Threatens To End Pfizer Alliance On Aricept Following Wyeth Acquisition

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai announced that it "has the right" to terminate a product development and business alliance agreement for its Alzheimer's treatment Aricept (donepezil) if Pfizer acquires Wyeth

You may also be interested in...



Pfizer and Eisai Will Continue Aricept Deal, But Add Lyrica To The Agreement

A potential sticking point in Pfizer's acquisition of Wyeth has been resolved - the big drug maker and Eisai have agreed to continue co-promoting Aricept (donepezil) in the U.S., Europe and Japan. However, Eisai will regain full Japanese rights to the Alzheimer's blockbuster at the end of 2012, while the rest of the collaboration will remain in place until 2022

Pfizer and Eisai Will Continue Aricept Deal, But Add Lyrica To The Agreement

A potential sticking point in Pfizer's acquisition of Wyeth has been resolved - the big drug maker and Eisai have agreed to continue co-promoting Aricept (donepezil) in the U.S., Europe and Japan. However, Eisai will regain full Japanese rights to the Alzheimer's blockbuster at the end of 2012, while the rest of the collaboration will remain in place until 2022

Eisai To Reinforce Oncology R&D, Sales To Achieve 17% Income Rise

TOKYO - Quadrupling profits in the business year from the preceding year and forecasting a solid 17.5 percent rise in the current year, Eisai Co., the fourth-largest Japanese pharma and the only one reporting profit among the four, said it will further reinforce its oncology drug development and sales while accelerating global distribution of Alzheimer's treatment Aricept

Related Content

UsernamePublicRestriction

Register

SC071610

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel